[Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma].

Abstract

Cladribine is a purine analogue that is resistant to degradation by adenosine deaminase. We describe the efficacy of cladribine monotherapy in 8 patients with relapsed or refractory indolent non-Hodgkin lymphoma. The median age of the patients was 57 years. All patients were given 1-3 courses of cladribine monotherapy at 0.09 mg/kg/day continuous infusion for 7 days. Although all patients had been treated with rituximab and CHOP-like regimens, the response rate was excellent (85.7%). Thus we consider that cladribine is the first treatment of choice in the patients with relapsed or refractory indolent lymphoma.

• Authors: Yasuhiro Nakashima, Toshihiro Shimada, Yu Yamada, Ilseung Choi, Yuji Yufu, Naokuni Uike
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 45 Issue 7 Pg. 568-70 (Jul 2004) ISSN: 0485-1439 [Print] Japan
• PMID: 15359918 (Publication Type: English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Cladribine

Topics

• Aged
• Antineoplastic Agents (administration & dosage)
• Cladribine (administration & dosage)
• Female
• Follow-Up Studies
• Humans
• Infusions, Intravenous
• Lymphoma, B-Cell (drug therapy)
• Male
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy)
• Retrospective Studies
• Treatment Outcome